GlassScriptPhysician profile
John R Markeson
NPI 1861503419
$3,850.28
in general payments reported to CMS, 2019-2025
41 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $524 · 2021: $713 · 2022: $340 · 2023: $466 · 2024: $819 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $520.29 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $393.85 | 2020-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $299.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $286.00 | 2019-2024 | Prolia, Evenity, Tavneos |
| Pfizer INC. | $262.76 | 2019-2024 | |
| Abbvie INC. | $252.09 | 2021-2025 | |
| Glaxosmithkline, LLC. | $245.27 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $181.00 | 2020-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $141.47 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $138.21 | 2019-2024 | |
| Dexcom, INC. | $121.18 | 2019-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $99.28 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $82.53 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.04 | 2020-2025 | Xifaxan |
| Exact Sciences Corporation | $66.16 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Markeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.